Antibacterial activity of hinokitiol against both antibiotic-resistant and -susceptible pathogenic bacteria that predominate in the oral cavity and upper airways.
Aggregatibacter actinomycetemcomitans
/ drug effects
Anti-Bacterial Agents
/ pharmacology
Bacteria
/ classification
Cell Line, Tumor
/ drug effects
Cell Survival
/ drug effects
Epithelial Cells
/ drug effects
Fusobacterium nucleatum
/ drug effects
Humans
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Microbial Sensitivity Tests
Monoterpenes
/ pharmacology
Mouth
/ microbiology
Porphyromonas gingivalis
/ drug effects
Prevotella intermedia
/ drug effects
Staphylococcus aureus
/ drug effects
Streptococcus mutans
/ drug effects
Streptococcus pneumoniae
/ drug effects
Streptococcus pyogenes
/ drug effects
Streptococcus sobrinus
/ drug effects
Tropolone
/ analogs & derivatives
Streptococcus pneumonia
antibacterial agent
hinokitiol
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
07
02
2019
revised:
17
04
2019
accepted:
06
05
2019
pubmed:
21
5
2019
medline:
23
7
2019
entrez:
21
5
2019
Statut:
ppublish
Résumé
Hinokitiol, a component of the essential oil isolated from Cupressaceae, possesses antibacterial and antifungal activities and has been used in oral care products. In this study, the antibacterial activities of hinokitiol toward various oral, nasal and nasopharyngeal pathogenic bacteria, including Streptococcus mutans, Streptococcus sobrinus, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia, Fusobacterium nucleatum, methicillin-resistant and -susceptible Staphylococcus aureus, antibiotic-resistant and -susceptible Streptococcus pneumoniae, and Streptococcus pyogenes were examined. Growth of all these bacterial strains was significantly inhibited by hinokitiol, minimal inhibitory concentrations of hinokitiol against S. mutans, S. sobrinus, P. gingivalis, P. intermedia, A. actinomycetemcomitans, F. nucleatum, methicillin-resistant S. aureus, methicillin-susceptible S. aureus, antibiotic-resistant S. pneumoniae isolates, antibiotic-susceptible S. pneumoniae, and S. pyogenes being 0.3, 1.0, 1.0, 30, 0.5, 50, 50, 30, 0.3-1.0, 0.5, and 0.3 μg/mL, respectively. Additionally, with the exception of P. gingivalis, hinokitiol exerted bactericidal effects against all bacterial strains 1 hr after exposure. Hinokitiol did not display any significant cytotoxicity toward the human gingival epithelial cell line Ca9-22, pharyngeal epithelial cell line Detroit 562, human umbilical vein endothelial cells, or human gingival fibroblasts, with the exception of treatment with 500 μg/mL hinokitiol, which decreased numbers of viable Ca9-22 cells and gingival fibroblasts by 13% and 12%, respectively. These results suggest that hinokitiol exhibits antibacterial activity against a broad spectrum of pathogenic bacteria and has low cytotoxicity towards human epithelial cells.
Identifiants
pubmed: 31106894
doi: 10.1111/1348-0421.12688
doi:
Substances chimiques
Anti-Bacterial Agents
0
Monoterpenes
0
Tropolone
7L6DL16P1T
beta-thujaplicin
U5335D6EBI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-222Subventions
Organisme : JSPS KAKENHI
ID : 17H04367
Organisme : JSPS KAKENHI
ID : 16K11439
Organisme : JSPS KAKENHI
ID : 18K19638
Organisme : JSPS KAKENHI
ID : 17K19747
Organisme : Kobayashi International Scholarship Foundation
Organisme : Kobayashi Pharmaceutical Co., Ltd
Informations de copyright
© 2019 The Societies and John Wiley & Sons Australia, Ltd.